Search research articles
Contact Us
Filters
Showing results (21-30 of 352) with videos related to
Page
of 36
Sort By:
The New England Journal of Medicine
|
September 3, 2025
Malnutrition in Older Adults
Iris K Minichmayr, Markus Zeitlinger
Antibiotics (Basel, Switzerland)
|
December 24, 2021
Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time-Kill Approaches
Wisse van Os, Markus Zeitlinger
Pharmaceutics
|
August 23, 2020
Use of Supplemented or Human Material to Simulate PD Behavior of Antibiotics at the Target Site In Vitro
Alina Nussbaumer-Pröll, Markus Zeitlinger
Clinical Pharmacokinetics
|
February 27, 2020
Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents
Valentin Al Jalali, Markus Zeitlinger
Clinical Pharmacokinetics
|
January 15, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
Valentin Al Jalali, Markus Zeitlinger
The Journal of Antimicrobial Chemotherapy
|
January 4, 2024
Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections
Wisse van Os, Markus Zeitlinger
Wiener Klinische Wochenschrift
|
October 20, 2025
Economic, cultural and social inequalities in potentially inappropriate medication-An Austrian perspective
Christian Schoergenhofer, Thorsten Bischof, Markus Zeitlinger
The Journal of Antimicrobial Chemotherapy
|
June 27, 2018
Comment on: Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass
Martin Andreas, Markus Zeitlinger, Doris Hutschala
The Journal of Antimicrobial Chemotherapy
|
December 30, 2022
A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship
Erlangga Yusuf, Markus Zeitlinger, Sylvain Meylan
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 6, 2019
Pharmacokinetic Imaging with Radiolabeled Molecularly Targeted Anticancer Drugs
Martin Bauer, Markus Zeitlinger, Oliver Langer
Page
of 36
Search research articles
Search
Showing results (21-30 of 352) with videos related to
Sort By:
Page
of 36
The New England Journal of Medicine
|
September 3, 2025
Malnutrition in Older Adults
Iris K Minichmayr, Markus Zeitlinger
Antibiotics (Basel, Switzerland)
|
December 24, 2021
Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time-Kill Approaches
Wisse van Os, Markus Zeitlinger
Pharmaceutics
|
August 23, 2020
Use of Supplemented or Human Material to Simulate PD Behavior of Antibiotics at the Target Site In Vitro
Alina Nussbaumer-Pröll, Markus Zeitlinger
Clinical Pharmacokinetics
|
February 27, 2020
Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents
Valentin Al Jalali, Markus Zeitlinger
Clinical Pharmacokinetics
|
January 15, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
Valentin Al Jalali, Markus Zeitlinger
The Journal of Antimicrobial Chemotherapy
|
January 4, 2024
Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections
Wisse van Os, Markus Zeitlinger
Wiener Klinische Wochenschrift
|
October 20, 2025
Economic, cultural and social inequalities in potentially inappropriate medication-An Austrian perspective
Christian Schoergenhofer, Thorsten Bischof, Markus Zeitlinger
The Journal of Antimicrobial Chemotherapy
|
June 27, 2018
Comment on: Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass
Martin Andreas, Markus Zeitlinger, Doris Hutschala
The Journal of Antimicrobial Chemotherapy
|
December 30, 2022
A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship
Erlangga Yusuf, Markus Zeitlinger, Sylvain Meylan
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 6, 2019
Pharmacokinetic Imaging with Radiolabeled Molecularly Targeted Anticancer Drugs
Martin Bauer, Markus Zeitlinger, Oliver Langer
Page
of 36